Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about FDA approves treatment for any solid tumor with a specific genetic feature
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
- Read more about USFDA approves subcutaneous Actemra to treat giant cell arteritis
The U.S. Food and Drug Administration expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This new indication provides the first FDA-approved therapy, specific to this type of vasculitis.

[adsense:336x280:8701650588]
- Read more about Tonix Pharmaceuticals presented analyses of Potential Moderators of Treatment response to USFDA
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health challenges, presented entitled “Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder: Mediators and Moderators of Treatment Response” (Poster No. 3001130) at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry in San Diego. The poster can be found on the Scientific Presentations page on Tonix’s website. A moderator is a characteristic of study participants that is associated with a treatment response.
- Read more about NPPA revises prices of 5 scheduled drug formulations
Price regulator NPPA reviewed the maximum prices for five programmed drug formulations used in the treatment of various ailments, including seizures, epilepsy and allergic rhinitis, among others.
- Read more about Cutting-edge analysis reveals how different drugs interact with the same target
Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug–target binding in a physiological environment and at clinically-relevant concentrations. They revealed differences between the three drugs in the size and structure of the complexes formed, which may explain differences in the drugs’ clinical efficacy. This technique could help optimize future drug design.
- Read more about Health Minister J P Nadda launches Pneumococcal Conjugate Vaccine (PCV) under Universal Immunization Programme
No Child should die in the country from Vaccine Preventable Diseases. We stand committed to reducing child deaths: Shri J P Nadda

“No child should die in the country from Vaccine Preventable Diseases” is the Goal & Commitment of our government. We stand committed to reducing child deaths and providing a healthier future to our children.” Shri J P Nadda, Union Minister for Health and Family Welfare stated this as he announced the introduction of pneumococcal conjugate vaccine (PCV) in the Universal Immunization Programme (UIP) of the country in a function at Mandi, today. Terming this as an historic moment and an exemplary step in India’s immunization programme, the Union Health Minister added that the Government is committed to reducing morbidity and mortality in children. Strengthening routine immunization is an essential investment in India’s children and will ensure a healthy future of the country, he noted.
- Read more about Alembic Pharmaceuticals receives USFDA approval for Fenofibric Acid Delayed Release Capsules
Alembic Pharmaceuticals Limited announced that the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Fenofibric Acid Delayed-Release Capsules, 45 mg and 135 mg.
- Read more about Abeona Therapeutics announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT
Abeona Therapeutics Inc.a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced updated data from the ongoing gene therapy clinical trial for Sanfilippo syndrome Type A (MPS IIIA) at the American Society Gene and Cell Therapy (ASGCT) 20th Annual Meeting. The ongoing Phase 1/2 trial for ABO-102 (AAV-SGSH) is a first-in-man clinical trial utilizing a single intravenous injection of AAV gene therapy for subjects with Sanfilippo syndrome (MPS IIIA), a rare autosomal-recessive lysosomal storage disease.
- Read more about Scientist develop new battery-free medical implants by using body’s fluids
Scientists have developed a new energy storage device that works with fluids in the human body and could lead to more durable and battery-free pacemakers and other implantable medical devices. The bio-friendly energy storage system called biological supercapacitor is powered by charged particles, or ions, from body fluids like blood serum and urine. Pacemakers - which help regulate abnormal heart rhythms - and other implantable devices have saved countless lives.
- Read more about Plan to open Jan Aushadhi stores at railway stations & bus stands: Govt.
Plans are underway to open the Jan Aushadhi stores to about 1,000 major railway stations in India as part of the government's commitment to make quality medicines available at low cost to the public. Plans are also underway to open such outlets in bus stands in different states with the aim of bringing the network back to small towns and villages.